Ocumetics Announces Optimized Lens Delivery System in Collaboration with Medicel

(TheNewswire)

Calgary, Alberta – TheNewswire - December 9, 2025 -Ocumetics Technology Corp . (“Ocumetics” or the “Company”)(TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO), a leader in next generationophthalmic technology, is pleased to announce that Medicel AG(“Medicel”), a global leader in ophthalmic device deliverysystems, has further modified its lens delivery technology in responseto surgeon input following first-in-human lens implantationprocedures.

“The surgeon who performed our first-in-humanimplantations has been instrumental in shaping further improvements inthe design of our lens delivery system that will be invaluable as wework to optimize the final configuration of the Ocumetics Lens,”said Dean Burns, President and CEO of Ocumetics.  “Medicel’swillingness to innovate rapidly and refine their delivery platform forthe Ocumetics Lens based on surgeon feedback demonstrates the strengthof our partnership and Medicel’s commitment to supporting nextgeneration accommodating intraocular lens technologies.”

The updated intraocular lens delivery system isdesigned to optimize loading efficiency, streamline implantationprocedures, and assure its compatibility with the unique mechanicalproperties of the Ocumetics Lens.  These improvements should allowsmoother insertion and maximize surgeon acceptance of the OcumeticsLens as the Company progresses toward expanded clinicalstudies.

The Company intends to use the optimized lens delivery system for itsupcoming Group 2 surgeries planned for early 2026.

Forward Looking Statement RegardingMedicel

Ocumetics anticipates continued collaboration with Medicel as bothcompanies work toward ensuring optimal delivery solutions forOcumetics’ upcoming stages of clinical development. The Companybelieves that Medicel’s longstanding leadership in ophthalmic deviceengineering positions them as an ideal partner as Ocumetics advancestoward planned regulatory engagements and expanded trials.

About Ocumetics

Ocumetics Technology Corp. ( TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO)is a Canadian research and product development company that is dedicated to developing advanced visioncorrection solutions that enhance the quality of life for patients. Through innovative research and development, Ocumetics aims totransform the field of ophthalmology with state-of-the-art intraocularlenses and other vision-enhancing technologies.

Ocumetics is in the first-in-human early feasibilitystudy phase of a game-changing technology for the ophthalmic industry. Ocumetics has developed an intraocular lens that fits within thenatural lens compartment of the eye, potentially to eliminate the needfor corrective lenses.  It is designed to allow the eye’s naturalmuscle activity to shift focus from distance to near, providing clearvision at all distances without the help of glasses or contact lenses.

FOR FURTHER INFORMATION, PLEASECONTACT:

Dave Burwell

Director, Investor Relations

dave.burwell@ocumetics.com

(403) 410-7907

Neither the TSXVenture Exchange nor its Regulation Services Provider (as that term isdefined in the policies of the TSX Venture Exchange) acceptsresponsibility for the adequacy or accuracy of this release.

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKINGINFORMATION: This news release includes certain “forward-lookingstatements” under applicable Canadian securities legislation. Forward-looking statements include, but are not limited to,statements with respect to the commencement, timing and scope of theresearch and development to be conducted by the Company mentionedabove.  Forward-looking statements are necessarily based upon anumber of estimates and assumptions that, while considered reasonable,are subject to known and unknown risks, uncertainties, and otherfactors which may cause the actual results and future events to differmaterially from those expressed or implied by such forward-lookingstatements. Such factors include but are not limited to: operationalmatters, historical trends, current conditions and expected futuredevelopments, access to financing as well as other considerations thatare believed to be appropriate in the circumstances.  There can be noassurance that such statements will prove to be accurate, as actualresults and future events could differ materially from thoseanticipated in such statements. Accordingly, readers should not placeundue reliance on forward-looking statements.  The Company disclaimsany intention or obligation to update or revise any forward-lookingstatements, whether as a result of new information, future events orotherwise, except as required by law.

Copyright (c) 2025 TheNewswire - All rights reserved.